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Abstract
Background: Treatment of hepatitis C (HCV) among people who inject drugs (PWID) is a critical component of
efforts to eliminate viral hepatitis. A recent study found high HCV prevalence among PWID in two cities, Pretoria
(84%) and Cape Town (44%). Very few (< 5%) HCV-infected individuals attended follow-up appointments. This sub-
study explores differences between stated desire for cure and appointment attendance in light of perceived
facilitators and barriers to HCV treatment and care access among PWID.
Method: Two sets of semi-structured interviews were implemented in a group of HCV-infected participants
opportunistically sampled and recruited at harm reduction service sites. Initial interviews, conducted before the
planned hospital appointment date, asked participants (N = 17, 9 in Pretoria and 8 in Cape Town) about past
experiences of healthcare provision, plans to attend their referral appointment and perceived barriers and
facilitators to seeking hepatitis treatment. Second interviews (n = 9, 4 in Pretoria, 5 in Cape Town), conducted after
the planned referral appointment date, asked about appointment attendance and treatment experience. Trained
social scientists with experience with PWID conducted the interviews which were recorded in detailed written
notes. Data was thematically analysed in NVivo 11.
Results: Despite routine experiences of being stigmatised by the healthcare system in the past, most participants
(n = 16, 94%) indicated a desire to attend their appointments. Attendance motivators included the desire to be
cured, fear of dying and the wish to assist the research project. Perceived barriers to appointment attendance
included fear of again experiencing stigmatisation and concerns about waiting periods and drug withdrawal.
Perceived facilitators included the knowledge they would be treated quickly, and with respect and access to opioid
substitution therapy. In the end, very few participants (n = 5) went to their appointment. Actual barriers to
attendance included lack of finances, lack of urgency and forgetting and fatalism about dying.
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Conclusions: South Africa can learn from other countries implementing HCV treatment for PWID. Successful linkage
to care will require accessible, sensitive services where waiting time is limited. Psychosocial support prior to
initiating referrals that focuses on building and maintaining a sense of self-worth and emphasising that delayed
treatment hampers health outcomes is needed.
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Background
South Africa has a large-scale national public healthcare
system that provides prevention, care and treatment to the
high proportion of the population affected by HIV. This
progressive and extensive state approach, however, has not
extended to people who inject drugs (PWID) despite their
increased risk of contracting HIV. Criminalisation of drug
use, a national reluctance to fully embrace harm reduction
and high levels of stigma towards PWID [1], manifest in an
absence of state-provided harm reduction services and
frequently substandard healthcare provision when PWID
attempt to access public services [2, 3]. In 2017, the largest
(HIV-focused) needle and syringe programmes were run
through non-governmental organisations (TB HIV Care
and Out Well-Being) and were funded by international
funders,1sometimes against active obstruction from state
institutions. It is therefore not surprising that despite the
country committing to the World Health Organization
(WHO) target of eliminating viral hepatitis by 2030 [4],
and despite international recognition that approximately a
third of new HCV infections result from injecting drug use
[5], there has been very little attention to injecting drug use
as a mode of HCV transmission. Although treatment via
specialist facilities is available in some cities, barriers to ac-
cess are high, and there are no government services that
routinely provide community-based testing and treatment
for viral hepatitis for PWID. The Viral Hepatitis Initiative
for Key Populations in South Africa (the Viral Hepatitis
Initiative) was a cross-sectional survey implemented in
seven South African cities (recruiting PWID in three of
these) between August 2016 and October 2017. This
survey included testing for HCV, HBV surface antigen and
HIV among PWID who were opportunistically sampled as
they accessed health services and it confirmed a high over-
all HCV seroprevalence of 55% among PWID (84% in
Pretoria, 44% in Cape Town and 35% in Durban) [6].2 Un-
like HIV, HCV infection is curable and treatment is be-
coming easier with direct acting antiviral therapy (DAAs)
[7]. In South Africa, DAAs for HCV are not registered but
can be accessed after obtaining a Section 21 approval from
the South African Health Products Regulatory Authority
(SAHPRA). Accessed DAAs are either self-funded, funded
by medical aids or state-funded through motivation at
academic teaching hospitals.
HCV treatment for PWID is recommended in inter-
national guidelines [8], and treatment adherence and
cure rates amongst PWID accessing DAAs, at > 90%, are
acceptable [9, 10]. Yet, globally, treatment uptake re-
mains unacceptably low [10–12]. In the Viral Hepatitis
Initiative, people who tested HCV antibody positive were
offered linkage to HCV care. This was unescorted, and
the nature of the services on offer differed depending on
what was available: In Pretoria, referrals were made to
Tshwane District hospital for liver monitoring and sup-
port. In Cape Town, HCV-infected individuals received
referrals and appointment dates for the Groote Schuur
Hospital Liver Clinic, which is affiliated to the University
of Cape Town and the only facility that routinely applied
for DAAs to treat HCV-infected individuals using the
Section 21 avenue.
Early on in the Viral Hepatitis Initiative, implementing
staff and referral hospital teams noticed that in both
Pretoria and Cape Town newly diagnosed individuals
(almost exclusively PWID) would indicate a desire for
follow-up support and treatment but then would not
attend initial or rescheduled appointments. Low HCV
treatment uptake among PWID in a range of contexts
[10, 11] is linked to various barriers, including individual,
social and health system level barriers [13]. However, there
is no literature that speaks to this in the South African
context. This study, a sub-study of the Viral Hepatitis
Initiative, sought to understand barriers and facilitators to
care access.
Method
The Viral Hepatitis Initiative took place in sites that
routinely provided harm reduction and HIV preven-
tion services for PWID. In two of the sites (Pretoria
and Cape Town), PWID who had tested HCV posi-
tive on point of care tests were invited to participate
in this study, which was structured into two sets of
semi-structured qualitative interviews. The first inter-
view, implemented before the planned hospital
1The Step Up Project, which seeks to provide HIV prevention services
to people who inject drugs, was initiated in 2015 in three cities (Cape
Town, Pretoria and Durban) and extended to a fourth in 2017.
2The Viral Hepatitis Initiative was implemented by TB HIV Care in
Partnership with OUT Well-Being, Anova Health Institute, the Uni-
versity of Cape Town’s Division of Hepatology and the National Insti-
tute of Communicable Diseases.
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appointment date, asked participants to reflect on
past experiences of healthcare provision, plans to at-
tend their referral appointment and perceived facilita-
tors and barriers to seeking viral hepatitis treatment.
The second interview, implemented after the planned
appointment date, asked participants about appoint-
ment attendance. Those that had attended were then
asked about their treatment experience. Those that had
not attended were asked about their reasons for non-
attendance. This line of questioning was based on the
discrepancies service providers had reported between
initial responses to a positive HCV diagnosis and
follow-up health-seeking behaviour.
All interviews occurred between July and December
2017. The time between the interviews was dependent
on referral appointment date, which at the specialist
treatment centre in Cape Town was sometimes months
in advance. In some cases, first and second interviews
were a week apart; in other cases, they were months
apart. However, all second interviews were conducted
within 6 weeks of the referral appointment date.
Two trained social scientists conducted the interviews.
AV, the Cape Town interviewer, is a medical anthropologist
who, at the time of the research, had 7 years of experience
conducting research with people who use drugs, including
in the implementing organisation. AM, also a trained an-
thropologist and the Pretoria interviewer, had worked as a
counsellor in the implementing organisation for 2 years at
the time of the research. Both interviewers were involved in
the parent study: AV was in the management team and
worked across all study sites with staff teams; AM was an
implementing team member in Pretoria.
In both sites, recruitment and sampling for the first
interview was opportunistic. Participants were approached
if they were eligible and at the fixed service provision sites
while the researchers were available. In Cape Town, staff
who had been involved in the parent study (and were
privy to individuals’ HCV status) informed participants
about the potential study and linked interested partici-
pants with AV on days that AV was at the site. In Pretoria,
AM approached potential participants herself. Inclusion
was entirely based on who arrived first. The result was a
sample that was largely reflective of the parent study. The
majority (n = 15) were male; the lower number of women
(n = 2) reflects the lower number of women participating
in the parent project in the two included cities (15%). The
age of participants ranged between 29 and 45, with a mean
age of 36. Four participants self-classified as black, 6 as
white and 7 as of mixed ancestory. The slightly (10%)
higher proportion of white participants in this study com-
pared to the parent study reflects the demographic profile
of people accessing the fixed services, rather than mobile
services in Pretoria. Eleven (65%) of the participants were
sleeping rough.
Participation was not remunerated. As an add-on
study to a parent study that was incorporated into ser-
vice provision and therefore not remunerated, there was
no available budget. In the context of people using drugs
for whom time is often directly linked to earnings that
can stave off withdrawal, this may have shaped who was
willing to talk to us. This study included 17 participants
in the first round (9 in Pretoria and 8 in Cape Town). A
subset of these took part in the second round of inter-
views (9 in total, 4 in Pretoria, 5 in Cape Town). This
met our set recruitment targets of between 12 and 20
participants in initial interviews and between 8 and 15 in
the second interviews. In Pretoria, we had no inclusion
refusals (in Cape Town, we did not ask recruitment staff
to document these refusals). The lack of incentives may,
in fact, have had the positive impact of meaning that the
people who spoke to us likely did so out of genuine con-
cern for improving the health conditions they face daily.
Eligibility required participants to indicate their will-
ingness to participate in both interviews, but as indicated
in our targets, a drop off between interview rounds was
expected. This was because participants did not all have
contact details or regular life patterns. Inclusion in the
second interview either relied on their actively seeking
out the researchers to make an arrangement or their
being present, willing and able to talk at a time the
researchers were available on site during the research
period. In Pretoria, all of those who were not in the
second interview returned to talk to AM but after we
had closed the recruitment period. In Cape Town, the
two people who did not participate in the second inter-
views both indicated that they were busy at the re-
quested second interview time.
Our work was undoubtedly affected by the extent of
relationships with the participants. AV knew two partici-
pants well from having trained them on qualitative
research methods, but the rest she either did not know
or only knew by sight. AM knew all the participants
from having interacted with them during service
provision. This may have meant that participants were
more likely to provide answers they thought the inter-
viewer wanted to hear. At the same time, people who
use drugs have little incentive to explain life worlds to
people they do not know [14, 15] and it may be that the
candidness of the responses we received was to some
extent related to a level of trust built on long-standing
relationships. In recruitment and interview processes, it
was emphasised to the respondents that their answers
would in no way affect their access to services.
The interview location was determined by where par-
ticipants indicated they were most comfortable. In Cape
Town, where the facility was more crowded, most (n =
10) were conducted outside, in a quiet corner of a public
square close to the drop-in centre, outside of earshot of
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other people. The rest (n = 4) were conducted in-facility
in a clinical or counselling room behind closed doors. In
Pretoria, where there was less immediate public space
and more privacy within the facility, most interviews
were conducted in a counselling room (n = 7) and when
this was occupied, the boardroom (n = 4), with only 2
conducted outside. Interview time length ranged be-
tween 20 and 45min, with most—across both inter-
views—taking approximately 30 min.
Voice recorders were not used because researcher
desires to keep the conversations as pressure-free as
possible and concerns about confidentiality and secur-
ity. The interview sites were sites of frequent theft of
valuable items, and before this study, one of AV’s
voice-recorders was stolen during a research process.
Interviews were, therefore, recorded through detailed
ethnographic written notes, which included—amongst
other things—information about interview location,
affect and past engagement with the participants.
These notes were securely stored off-site and typed
up as soon as possible, mostly within hours of the
interview completion. Where direct quotes were writ-
ten down word-for-word during the interview process,
these have been included in the text, though chal-
lenges in finding time with participants meant they
were not member checked. Both interviewing re-
searchers analysed the interview write ups and separ-
ately developed coding matrices until saturation was
reached. The researchers then compared matrices and
developed a unified framework for all the interviews.
These were then coded in NVivo 11 by one re-
searcher (AV) and cross-checked by the second (AM).
Research was approved by the University of Cape
Town Human Research Ethics Committee (reference
number 320/2017). Informed consent was obtained from
all participants. Pseudonyms are used in this paper, and
identifying features of participants have been withheld.
Results
Desire to attend appointments
All but one of the participants (n = 16, 94%) indicated,
mostly emphatically, that they would attend their initial
hospital appointments. They reported concerns about
their health and the desire to be cured. This was particu-
larly pressing for the four participants that indicated
they were experiencing symptoms that they ascribed to
hepatitis (mostly lethargy), but these concerns were also
expressed by those not experiencing symptoms. As
Taariq (male, 30, Cape Town) said, “I care about my
health. I have kids and I want to be healthy for them…I
want to be cured.”
The flipside to this desire for cure was, for some, the
fear of illness and dying. Jesse (male, 44, Cape Town) ex-
plained that he was planning to attend his appointment
“because I don’t want to die...” On being asked whether
he thought hepatitis was going to result in his death he
said, “Yes. Nathalie Cole died of hepatitis last year, and
she was rich. If a rich woman died, what is my chance
[of surviving]?” Shafiek (male, 31, Cape Town) explained
that he did not want to “be like all those others who go
[die] so easily”. He explained that he had heard of four
people who had tested positive for hepatitis dying
recently, two were his friends. He (rightly or wrongly) at-
tributed these deaths to hepatitis.
The intention to attend appointments was also shaped
by desire to assist the implementing teams (through
gathering information) and/or to see whether healthcare
systems had improved since the project team had
engaged with staff at the referral centres. Edward (male,
35, Pretoria) said, on enquiry if he would attend the
facility he was referred to, that he would attend for the
research and that he would “even take a notebook with”,
although previously he had stated he would not normally
go, even if methadone was made available to him. Wolfgang
(male, 45, Pretoria) also stated he would visit the hospital
for the sake of the research as well as to see if the processes
had changed, whether the queues were shorter, if the hos-
pital provides HCV treatment and how people were being
treated by medical staff.
Past experiences of stigma
The voiced desire to attend appointments in all but one
participant (who expressed ambivalence) was despite
widely reported negative past experiences in the health-
care sector. These experiences included being blamed
for poor health, being made to feel ashamed for injecting
drugs, being told that people who use drugs are taking
attention away from deserving people and being made to
wait. For example, one participant, Taariq described his
last interaction with the public healthcare system: he
had gone to an emergency unit because he had uninten-
tionally injected heroin into the muscle of his arm and
not into his vein, resulting in extreme swelling. He said
he was left to wait an entire night before seeing a doctor
who “went off” when he revealed the cause of his injury.
He explained how the doctor shamed him by saying,
“there are other people out there with real sicknesses,
and now I must sit here with you”. Taariq said that the
worst thing was that the doctor did not even touch his
arm to assess the severity of the situation and told him
to go away and come back if it got worse so that they
could amputate his arm.
Participants also described privacy and confidentiality
breaches. Martin (male, 48, Cape Town) described a
doctor revealing his hepatitis status in front of other
people in a waiting room, and Jesse described a nurse
denying him a requested medical certificate for work,
telling him, in front of a corridor full of people, that he
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should rather go “hustle” (make money/beg) for money
in the main road—an activity associated with drug use.
As Greg (male, 30, Pretoria) summed up “ [the health-
care staff] are not helping you, they’re oppressing you”.
Participants also reported being ignored or made to
wait excessively—beyond what was generally expected
within the public healthcare system—as a form of active
punishment for people who used drugs. As Amina, (fe-
male, 31, Cape Town) described, “If they hear you are
using you must wait until there is someone available, if
there is someone.” Amina further described her inter-
action with clinic staff saying, “The lady saw on my arm
I was using, she didn’t want to communicate with me”
and going on to say that she was left waiting to be
served until last, despite other people having arrived
after her. “Being an addict at the hospital they treat you
unfair…it is like your body is nothing,” she said.
Perceived barriers and facilitators to care access
None of the participants had previously accessed hepa-
titis care, but all had concerns about how they would be
treated in the healthcare system. Gary (male, 30,
Pretoria) clearly stated that fear about how he would be
treated was a potential barrier to attending his appoint-
ment. He stated that now that he was maintaining his
personal hygiene, he would visit the hospital but when
he was living on the street and unable to access ablution
facilities, he would not “waste his time” because he
would leave without being attended to. Roger (male, 29,
Cape Town) said he was concerned because the way
people looked at him made him feel like a “freak”. How-
ever, despite the many past experiences of stigmatised
treatment, most people did not identify these as inhibi-
tors of accessing future treatment. Rather, what emerged
for most participants as pressing was withdrawal, and
fear thereof. As Roger (male, 29, Cape Town) explained,
“every addict fears cold turkey”, then correcting himself,
he said that what every drug user fears is not having
drugs available and leaving the place where they can reli-
ably make money. Johan (male, 45, Cape Town) said the
only thing that would stop him attending his appoint-
ment would be if he “didn’t have a fix laid out”.
A fear of waiting was closely associated with the con-
cerns of withdrawal. Shafiek said that he had never been
to a public healthcare facility because he knew waiting
was required, “I’m an addict. I don’t have the time and
patience to wait,” he explained. Roger said, “I hate sitting
long. I get irritable. A heroin addict hates sitting long.”
Wolfgang (male, 45, Pretoria) explained that people who
inject drugs are impatient because of the need to gener-
ate income but also indicated that immediate treatment
was not a reasonable expectation to have. These issues
(time required and fear of withdrawal) overshadowed
other possible imagined reasons for not going to an
appointment, which included possible life crises, such as
a child being extremely sick (n = 2), not having transport
money (n = 1) and work (n = 1).
When asked what would assist appointment attend-
ance, almost half the participants (n = 8) said that access
to either opioid substitution therapy or to enough drugs
for the day would increase the likelihood of them visiting
the hospital. Six participants indicated that knowing they
would receive treatment that was professional and of
high quality, or at least standard to that received by
other people, would increase their likelihood of visiting
the facility. As Jo (male, 25 Pretoria) stated “everyone
just wants to be treated the same, equal”. Five partici-
pants also indicated that knowing that they would be
quickly attended to would make a difference, noting that
these extended waiting periods fed into the time they
would be using to make money. This was explained by
Wolfgang (male, 45, Pretoria) who said that PWIDs do
not have the time to wait 3 or 4 h to be treated because
that they need to “zula” (hustle/make money/beg).
Reported reasons for non-attendance
Only five of all the participants (29%) attended their first
appointments at the referred hospitals (3 in Cape Town,
2 in Pretoria). We divide the reasons provided for lack
of attendance into three categories: lack of finances, lack
of urgency, and fatalism. Lack of finances was the key
reason for non-attendance participants provided. This
was despite the fact that most people had confidently
asserted that they would make sure they had enough
money through generating it in the days running up to
the appointment. Having no money was identified as
being linked to the need for a daily dose so as to avoid
withdrawal, transportation to and from the healthcare
facility, and basic needs, such as food for the day. As
Roger explained, “I didn’t have money and I wasn’t going
to go to town with no wake-up stuff [drugs]”. Damon
(male, 35, Pretoria) said that without money for trans-
port he was unwilling to walk to the facility in the cold,
with the expectation that he would more than likely be
treated badly by the facility’s staff. Mary (female, 43,
Pretoria) reiterated the above when she stated “[If] I
spend the whole day at the hospital. Who’s going to
make a plan for food that evening?”
Non-attendance was also simply described in terms of
forgetting. Brandon (male, 25, Cape Town) indicated
that, “I wanted to go, then I forgot my appointment date.
The date was only in October and in that time I was
drugging a lot.” Roger similarly said, “It slipped my mind
when I went home, only on the day of my appointment I
realised.” Forgetting was perhaps supported by a lack of
sense of urgency to attend the appointment. Johan
(male, 45, Cape Town) explained that getting treated
was simply not at the top of his priority list. One
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participant went away to an inpatient drug rehabilitation
centre at the time of his appointment. Another was able
to go but said that, “I know that the hepatitis virus attacks
you in a few years’ time, that’s why I’m taking it a bit
easy…” He said that he knew that hepatitis was a slow-
moving virus and this meant he did not feel the need to
respond immediately. Damon (male, 35, Pretoria) had a
similar mindset concerning the lack of urgency, but this
was also linked to a lack of available treatment by stating
“I don’t have to go now, I can go anytime, but I’ll go later
when I find out what they’ll do about it [HCV]”. This lack
of urgency, it seems, was partly supported by the fact that
participants seemed to have insufficient information about
what a positive diagnosis meant and the impact of HCV
on one’s health. Wolfgang (male, 45, Pretoria) stated that
they [PWID community] do not realise how dangerous
HCV is and that there needs to be more emphasis on edu-
cation on the subject.
Knowing the severity of the virus was not, however,
necessarily enough to motivate attendance in the face of
a lack of sense of self-worth and fatalism described by a
number of participants. Jesse (male, 44, Cape Town)
who had previously been diagnosed and not attended
appointments said, “I wasn’t really giving a shit if I live
or I die. Death didn’t seem that unappealing.” Similarly,
another participant explained that he did not care what
happened to him, saying, “you don’t give a f*&% just let
nature take its course”. Greg (30, male, Pretoria) ques-
tioned his right to care, saying, “Who am I? I brought
this to myself”, and another participant said there was
no point getting treatment if he was simply going to get
re-infected.
Reported attendance reasons and experiences
Various motivating factors were described by those who
did attend their appointments. These included trusting
the referral team and a reduction in “self-stigma” at hav-
ing learned how common HCV is in PWID (Jesse, 44,
Cape Town), active persuasion on the day of the ap-
pointment by staff members at the harm reduction facil-
ity (Taariq, male, 30, Cape Town) and the support of a
peer navigator (Wolfgang, male, 45, Pretoria). Edward
(male, 35, Pretoria) said that his attendance was not for
himself but rather to support the research project.
Attendance experiences varied. Both the Cape Town
participants described the sense of value they felt when
it was clear that the healthcare staff were expecting them
and did not stigmatise them for their use, but rather en-
couraged them to stay and wait precisely because they
were PWID. In Pretoria, Edward said that he waited the
whole day, was chided for his drug use loudly in front of
other waiting patients, suffered serious withdrawal and
eventually left at the end of the day without having re-
ceived assistance. Wolfgang, in contrast, was efficiently
moved through the system with support of the peer
navigator and described his appointment as acceptable,
if disappointing due to a lack of available treatment.
Discussion
The literature indicates a wide range of barriers to care
for HCV-infected PWID. These include reluctance to
engage with healthcare providers due to feelings of
shame about drug use [16] and prior experiences of
stigma and discrimination in the healthcare system
[17–19]. Related to this are high levels of patient mis-
trust of the healthcare system [16, 20] and fear of the
treatment process, often fuelled by stories of the side
effects of interferon-based therapy [16, 20–23]. Low
levels of perceived need for treatment [24] and/or a
corresponding lack of a sense of urgency, especially for
those who are asymptomatic [16, 20], and other health
priorities [22] all negatively impact on treatment seek-
ing. Practically, barriers such as distance from the place
of treatment to their place of residence, appointment time
[21] and for countries where this is a requirement, lack of
insurance and treatment costs [24] further undermine en-
gagement in treatment. Provider-level factors also contrib-
ute negatively. Medical staff are often reluctant to treat
PWID, especially if they are still injecting [25–27], for rea-
sons such as a mistrust in the person to adhere to treat-
ment because they use drugs, as well as concerns about
costs, co-morbidities and reinfection [25, 26, 28, 29].
These barriers are all compounded by the criminalisa-
tion of drug use [10, 30].
Our research, the first of this nature to be conducted
in South Africa, echoes many of the findings from other
parts of the world. Most notably, participants reported
past experiences of stigma and high levels of mistrust of
the healthcare system, low levels of urgency and prac-
tical barriers to appointment attendance. Our research
was, however, structured differently to other published
literature in that we explored reported self-expectations
of behaviour and anticipated barriers as well as actual
behaviour and experienced barriers. This reveals a mis-
match between the participants stated intention (and
perceived capacity) to attend their appointments and
their actual attendance. In initial interviews, individuals
seemed confident that past experiences of stigma would
not affect their attendance and though they recognised
lack of resources as a potential barrier to attendance,
they also reported confidence that they would manage
to muster enough resources to get to their appointments
and avoid withdrawal. This did not prove to be the case,
and most participants did not attend their appointments.
It may be that in the first interview participants simply
wanted to assure the researchers that they were enacting
ideal behaviours as clients of the harm reduction services
they were accessing. Our impression was, however, that
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they were assuring themselves that they would act in the
best interests of their own health in the future. This
motivation, however, waned in the interim between the
interview and the appointment date, for some this was
overridden by a combination of lack of urgency, low
sense of self-worth and lack of conviction that life is
worth living.
The inaccuracy in envisioning, or verbalising, potential
barriers to treatment access contrasted with the partici-
pants’ ability to conceptualise potential facilitators. It
was the lack of opioid substitution therapy, or sufficient
resources to facilitate transport and avoid withdrawal
while waiting for services, that were reported most fre-
quently to be the cause of appointment non-attendance.
Our work confirms that the key facilitators to care
access noted elsewhere—access to opioid substitution
therapy [12] continuity of care [23] and accessible, inte-
grated, treatment facilities [30, 31]—need to be ad-
dressed to enable cure and reduce risks of re-infection.
Our interviews with people who did attend their ap-
pointments all indicated the importance of established
relationships of trust as a key motivating factor for
ongoing treatment seeking. They further showed how
being well-treated by healthcare provider fostered an
important sense of self-worth. Psychosocial support pro-
cesses that build a sense of self-worth and the right to
care as could, as others suggest, be provided by peer
networks [29].
To the best of our knowledge, all the participants who
did attend their appointments participated in the second
interview. Furthermore, the percentage of our participants
(at 29%) who attended their appointment is far higher that
the percentage of all the referred participants of the larger
study that attended their appointments (< 1%). This indi-
cates a positive relationship between appointment attend-
ance and willingness to engage in the second interview,
which is likely bi-directional: the fact of the forthcoming
second interview supported clinic appointments, and
clinic appointment attendance encouraged second inter-
view participation. This suggests the importance of
follow-up of people referred, as well as the positive impact
rapport has on the willingness to engage and participate.
The study was subject to a number of limitations. The
lack of remuneration was likely to have shaped recruitment
and affected participation in second interviews. The small
sample size and qualitative nature of this study limits the
generalisability of the findings, and the relationship of the
researchers to the parent study may have influenced the
ways in which participants provided answers. We recognise
that other factors may have arisen had further interviews
been conducted. Additional insights would also have been
obtained if liver-related symptoms were captured; however,
the fact that not one of the four (3 men, 1 woman) that in-
dicated they were experiencing symptoms attended their
follow-up appointments indicates that that this was not ne-
cessarily correlated. Greater inclusion of women would
likely have highlighted additional issues. Women who use
drugs in South Africa [2] and beyond face substantial
additional barriers to healthcare access, including HCV
treatment [32]. Further research related to the challenges
women who use drugs face when attempting to access care
is needed. Finally, we acknowledge that not using voice re-
cordings may be seen to undermine the rigour of the data
due to researcher bias and resulted in the limited inclusion
of direct quotes. Given that the researchers are anthropolo-
gists, experienced in the field and trained in reflexive and
careful capture of social interaction, we suggest that the
detailed interview notes that were developed provided a nu-
anced picture of the factors at play.
Conclusion
HCV treatment can be affordable and is effective and well
tolerated by PWID. However, eliminating viral hepatitis
will require a concerted effort in which PWID are treated
as worthy individuals and supported in recognising them-
selves as such. Hepatitis services need to be accessible and
quick to reduce the financial and time costs of attendance.
They further need to be consistently friendly, as experi-
ences of stigma travel. As far as possible, services should
be integrated into holistic care, inclusive of opioid substi-
tution therapy. Services should also acknowledge and seek
to overcome the fact that verbal commitments to access
care may not align with actual capacities and that a desire
to attend services may be undermined by low self-worth.
Psychosocial support prior to initiating referrals that fo-
cuses on building and maintaining a sense of self-worth
and emphasising that delayed treatment hampers health
outcomes is needed.
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